Homocysteine levels and C677T polymorphism of methylenetrahydrofolate reductase in women with polycystic ovary syndrome

被引:75
作者
Orio, F
Palomba, S
Di Biase, S
Colao, A
Tauchmanova, L
Savastano, S
Labella, D
Russo, T
Zullo, F
Lombardi, G
机构
[1] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy
[2] Univ Catanzaro, Chair Obstetr & Gynecol, I-88100 Catanzaro, Italy
[3] MeriGen Mol Biol Lab, I-80131 Naples, Italy
关键词
D O I
10.1210/jc.2002-021142
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this study was to investigate the homocysteine (Hcy) levels and the C677T polymorphism of 5,10-methyl-enetetrahydrofolate reductase (MTHFR), a crucial factor of the Hey metabolism in young women with polycystic ovary syndrome (PCOS). Seventy young women with PCOS and another 70 healthy women with low folate intake were enrolled. Cases and controls were matched for age, body mass index, and allele frequency. Hey, vitamin B(12), and folate levels were measured, and a genetic analysis of 5,10-MTHFR at nucleotide 677 was performed in all subjects. No difference in mean Hcy levels was observed between PCOS women in comparison to the control group. Considering the different MTHFR polymorphism, no significant difference was found in serum Hey levels between subjects with PCOS and controls showing CC (10.4 +/- 3.1 us. 9.7 +/- 2.9 pmol/liter +/- SD) and CT genotypes (10.9 +/- 3.8 us. 11.0 +/- 3.2 pmol/liter SD). In subjects with a TT homozygous state, a significant (P < 0.05) difference was observed between PCOS and control women (11.5 +/- 3.9 as. 22.0 +/- 7.8 pmol/liter SD). In conclusion, our data show that in PCOS women, the serum Hey levels are normal, and the C677T polymorphism of MTHFR does not influence the Hey levels like in controls.
引用
收藏
页码:673 / 679
页数:7
相关论文
共 94 条
[1]   Plasma homocysteine concentrations in healthy volunteers are not related to differences in insulin-mediated glucose disposal [J].
Abbasi, F ;
Facchini, F ;
Humphreys, MH ;
Reaven, GR .
ATHEROSCLEROSIS, 1999, 146 (01) :175-178
[2]  
Abbate R, 1998, THROMB HAEMOSTASIS, V79, P727
[3]  
Adams M, 1996, QJM-MON J ASSOC PHYS, V89, P437
[4]   Plasma homocysteine and cardiovascular disease mortality [J].
Alfthan, G ;
Aro, A ;
Gey, KF .
LANCET, 1997, 349 (9049) :397-397
[5]   Methylenetetrahydrofolate reductase 677C→T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement:: a randomized controlled trial [J].
Ashfield-Watt, PAL ;
Pullin, CH ;
Whitting, JM ;
Clark, ZE ;
Moat, SJ ;
Newcombe, RG ;
Burr, ML ;
Lewis, MJ ;
Powers, HJ ;
McDowell, IFW .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2002, 76 (01) :180-186
[6]   Plasma total homocysteine levels in subjects with hyperinsulinemia [J].
Bar-On, H ;
Kidron, M ;
Friedlander, Y ;
Ben-Yehuda, A ;
Selhub, J ;
Rosenberg, IH ;
Friedman, G .
JOURNAL OF INTERNAL MEDICINE, 2000, 247 (02) :287-294
[7]   ENDOTHELIAL-CELL DAMAGE AND HOMOCYSTEINE [J].
BLANN, AD .
ATHEROSCLEROSIS, 1992, 94 (01) :89-91
[8]   POST-METHIONINE LOAD HYPERHOMOCYSTEINEMIA IN PERSONS WITH NORMAL FASTING TOTAL PLASMA HOMOCYSTEINE - INITIAL RESULTS FROM THE NHLBI FAMILY HEART-STUDY [J].
BOSTOM, AG ;
JACQUES, PF ;
NADEAU, MR ;
WILLIAMS, RR ;
ELLISON, RC ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 116 (01) :147-151
[9]   Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease -: The result of a meta-analysis [J].
Brattström, L ;
Wilcken, DEL ;
Öhrvik, J ;
Brudin, L .
CIRCULATION, 1998, 98 (23) :2520-2526
[10]   A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction [J].
Brugada, R ;
Marian, AJ .
ATHEROSCLEROSIS, 1997, 128 (01) :107-112